Le Lézard
Classified in: Health
Subject: PER

CUBEX LLC announces the appointment of Michael Boivin to President of CUBEX Medical


PHOENIX, July 18, 2018 /PRNewswire/ -- CUBEX LLC, a leading provider of first dose and emergency medication management technology to the institutional pharmacy market, announced the promotion of executive team member Michael Boivin, to the President of CUBEX's Medical Division. Effective immediately, Mr. Boivin will assume sole responsibility for the company's expansion of CUBEX's healthcare business, reporting to CUBEX's Chief Executive Officer, Anton Visser.  The organizational decision supports the company's continued focus on improving medication care, cost and compliance for better patient outcomes.

Starting his career with CUBEX in 2011, Mr. Boivin most recently held the title of Executive Vice President of Sales for both the animal health and medical divisions. His attention to these markets has helped CUBEX grow the businesses by delivering winning solutions to its veterinary and medical professionals and patients. In his new role, Mr. Boivin is responsible for overseeing all departments and sales functions for the medical division of the company.

"Michael's continued focus on customers and strategy of bringing industry expertise, technology and workflow solutions together to enrich the point of care experience has catapulted our growth," commented Mr. Visser.  "We couldn't be more confident in his ability to drive success."

About CUBEX LLC Medical

CUBEX® LLC's MedBank Medical Solutions division is a leading provider of innovative health care automation and cloud-based business intelligence solutions that enable institutional pharmacies and alternative healthcare providers to improve medication care, cost and patient outcomes.  Through their closed-loop ecosystem, which includes seamless integration with EMR's and Pharmacy Management Systems, MedBank medical solutions empower healthcare facilities to improve medication availability of emergent medications while at the same time increasing regulatory compliance. More information can be found at www.cubex.biz.

Media Contact:
Jennifer Burgus (CUBEX LLC)
760.707.3683
[email protected]

At Cubex, we are united in our vision to improve efficiencies for our customers. We are passionate about healthcare and helping those who deliver it by providing sophisticated solutions that allow them to focus their time on patient care. (PRNewsfoto/CUBEX LLC)

SOURCE CUBEX LLC


These press releases may also interest you

at 17:48
Hundreds of Community Leaders Kick Off Multi-city Convening in Bakersfield With a Simple Message: Do Not Cut San Joaquin Valley Programs & Services
On Wednesday, April 17, the San Joaquin Valley Health Fund (SJVHF) launched "Equity on the Road" a multi-city series of community town halls to deepen local understanding of state issues and to advocate for more resources in the San Joaquin Valley....

at 17:44
NOTICE TO THE MEDIA - Minister Holland to highlight Budget 2024: Fairness for Every Generation investments in students
The Honourable Mark Holland, Minister of Health, will host an event at the University of Waterloo to highlight the federal budget's investments to support students. The Minister will be joined by Bryan May, Parliamentary Secretary to the Minister of...

at 17:31
Global Radioimmunoassay Market to Grow at a Minimal CAGR of ~3% by 2030 | DelveInsight
The increasing need for radioimmunoassay is mainly driven by the rising occurrence of cancer, infectious diseases, and various other health conditions, along with a growing number of epidemics and pandemics and increasing health awareness. Moreover,...

at 17:00
Avicanna Announces Closing of Non-brokered Private Placement
Avicanna Inc. ("Avicanna" or the "Company") a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce that it has closed a non-brokered private...

at 16:46
Darling Ingredients Inc. to Release First Quarter 2024 Financial Results
Darling Ingredients Inc. announced today that it will host a conference call on Thursday, April 25, 2024, at 9 a.m. Eastern Time (8 a.m. Central Time) to discuss first quarter 2024 financial results, which will be released earlier that day, and...

at 16:45
FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Alecensa® (alectinib) for adjuvant treatment following tumor resection for patients with anaplastic...

More news about Health...


News published on and distributed by: